{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:39:09Z","timestamp":1790235549442,"version":"4.1.0"},"reference-count":61,"publisher":"BMJ","issue":"11","funder":[{"name":"French Ministry of Health","award":["grant reference number PHRC-I n\u00b013-077"],"award-info":[{"award-number":["grant reference number PHRC-I n\u00b013-077"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,10,7]]},"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Antineoplastic drugs (AD) are potentially carcinogenic and\/or reprotoxic molecules. Healthcare professionals are increasingly exposed to these drugs and can be potentially contaminated by them. Internal contamination of professionals is a key concern for occupational physicians in the assessment and management of occupational risks in healthcare settings. Objectives of this study are to report AD internal contamination rate in nursing staff and to identify factors associated with internal contamination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This trial will be conducted in two French hospital centres: University Hospital of Bordeaux and IUCT-Oncopole of Toulouse. The target population is nurses practicing in one of the fifteen selected care departments where at least one of the five studied AD is handled (5-fluorouracil, cyclophosphamide, doxorubicin, ifosfamide, methotrexate). The trial will be conducted with the following steps: (1) development of analytical methods to quantify AD urine biomarkers, (2) study of the workplace and organization around AD in each care department (transport and handling, professional practices, personal and collective protection equipments available) (3) development of a self-questionnaire detailing professional activities during the day of inclusion, (4) nurses inclusion (urine samples and self-questionnaire collection), (5) urine assays, (6) data analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol has been approved by the French Advisory Committee on the Treatment of Information in Health Research (CCTIRS) and by the French Data Protection Authority (CNIL). Following the opinion of the Regional Committee for the Protection of Persons, this study is outside the scope of the provisions governing biomedical research and routine care (n\u00b02014\/87). The results will be submitted to peer-reviewed journals and reported at suitable national and international meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03137641\">NCT03137641<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-033040","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T06:16:33Z","timestamp":1573452993000},"page":"e033040","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Study protocol for the assessment of nurses internal contamination by antineoplastic drugs in hospital centres: a cross-sectional multicentre descriptive study"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03137641","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Antoine","family":"Villa","sequence":"first","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health, Universit\u00e9 de Bordeaux, Bordeaux, France"},{"name":"Consultation de Pathologie Professionnelle et de I'environnement, CHU Timone, AP-HM, Marseille, France"},{"name":"Univ. of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health, Universit\u00e9 de Bordeaux, Bordeaux, France"},{"name":"Univ. of Bordeaux, Bordeaux, France"},{"name":"Laboratoire de Pharmacologie Clinique et Toxicologie, CHU de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bignon","sequence":"additional","affiliation":[{"name":"Bordeaux PharmacoEpi (BPE, CIC 1401), Universit\u00e9 de Bordeaux, Talence, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Martinez","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health, Universit\u00e9 de Bordeaux, Bordeaux, France"},{"name":"Univ. of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Rouyer","sequence":"additional","affiliation":[{"name":"Bordeaux PharmacoEpi (BPE, CIC 1401), Universit\u00e9 de Bordeaux, Talence, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mathoulin-Pelissier","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health, Universit\u00e9 de Bordeaux, Bordeaux, France"},{"name":"Univ. of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Baldi","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health, Universit\u00e9 de Bordeaux, Bordeaux, France"},{"name":"Univ. of Bordeaux, Bordeaux, France"},{"name":"GH Pellegrin, P\u00f4le de Sant\u00e9 Publique, Service de M\u00e9decine du Travail et Pathologies professionnelles, CHU de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Verdun-Esquer","sequence":"additional","affiliation":[{"name":"GH Pellegrin, P\u00f4le de Sant\u00e9 Publique, Service de M\u00e9decine du Travail et Pathologies professionnelles, CHU de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4140-1639","authenticated-orcid":false,"given":"Mireille","family":"Canal-Raffin","sequence":"additional","affiliation":[{"name":"Inserm U1219, Bordeaux Population Health, Universit\u00e9 de Bordeaux, Bordeaux, France"},{"name":"Univ. of Bordeaux, Bordeaux, France"},{"name":"Laboratoire de Pharmacologie Clinique et Toxicologie, CHU de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,11,10]]},"reference":[{"key":"2025121605112411000_9.11.e033040.1","unstructured":"Anonymous . [Healthcare]: French National Cancer Institute, 2019. Available: http:\/\/lesdonnees.e-cancer.fr\/Themes\/Soins [Accessed 12 Jul 2019]."},{"key":"2025121605112411000_9.11.e033040.2","unstructured":"Amira S . [Occupational risks by profession. 2010 Sumer study]. Synth\u00e8seStat' Direction de l\u2019animation de la recherche, des \u00e9tudes et des statistiques (DARES) 2014:1\u2013221."},{"key":"2025121605112411000_9.11.e033040.3","unstructured":"Anonymous . NIOSH alert: preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings (publication n\u00b02004-165. Centers for Disease Control and Prevention - National Institute for Occupational Safety and Health, 2004: 58."},{"key":"2025121605112411000_9.11.e033040.4","unstructured":"Anonymous . NIOSH list of antineoplastic and other hazardous drugs in healthcare settings (publication No. 2016\u2013161. Department of health and human services. Centers for Disease Control and Prevention. National Institute for Occupational Safety and Health, 2016: 42."},{"key":"2025121605112411000_9.11.e033040.5","doi-asserted-by":"publisher","DOI":"10.1136\/oem.49.12.855"},{"key":"2025121605112411000_9.11.e033040.6","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6955-9-15","article-title":"Cancer incidence and adverse pregnancy outcome in registered nurses potentially exposed to antineoplastic drugs","volume":"9","author":"Ratner","year":"2010","journal-title":"BMC Nurs"},{"key":"2025121605112411000_9.11.e033040.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198511073131901"},{"key":"2025121605112411000_9.11.e033040.8","first-page":"108","article-title":"Handling antineoplastic agents: urine mutagenicity in nurses","volume":"19","author":"Rogers","year":"1987","journal-title":"Image"},{"key":"2025121605112411000_9.11.e033040.9","doi-asserted-by":"publisher","DOI":"10.5271\/sjweh.1811"},{"key":"2025121605112411000_9.11.e033040.10","doi-asserted-by":"publisher","DOI":"10.1097\/00043764-199908000-00004"},{"key":"2025121605112411000_9.11.e033040.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.12.030"},{"key":"2025121605112411000_9.11.e033040.12","doi-asserted-by":"publisher","DOI":"10.1191\/1078155205jp155oa"},{"key":"2025121605112411000_9.11.e033040.13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ajim.22553","article-title":"Evaluation of adverse health risks associated with antineoplastic drug exposure in nurses at two Chinese hospitals: the effects of implementing a pharmacy intravenous admixture service","volume":"59","author":"Zhang","year":"2016","journal-title":"Am J Ind Med"},{"key":"2025121605112411000_9.11.e033040.14","doi-asserted-by":"publisher","DOI":"10.1136\/jech.39.2.141"},{"key":"2025121605112411000_9.11.e033040.15","doi-asserted-by":"publisher","DOI":"10.1136\/oem.45.9.581"},{"key":"2025121605112411000_9.11.e033040.16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/216507999304100301","article-title":"Adverse reproductive outcomes and occupational exposures among nurses: an investigation of multiple hazardous exposures","volume":"41","author":"McAbee","year":"1993","journal-title":"Aaohn J"},{"key":"2025121605112411000_9.11.e033040.17","doi-asserted-by":"publisher","DOI":"10.5271\/sjweh.523"},{"key":"2025121605112411000_9.11.e033040.18","doi-asserted-by":"publisher","DOI":"10.1097\/00043764-199706000-00013"},{"key":"2025121605112411000_9.11.e033040.19","doi-asserted-by":"publisher","DOI":"10.1097\/01.ede.0000246827.44093.c1"},{"key":"2025121605112411000_9.11.e033040.20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00381477"},{"key":"2025121605112411000_9.11.e033040.21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s004200050139","article-title":"Occupational exposure to antineoplastic agents and parameters for renal dysfunction","volume":"69","author":"Sessink","year":"1997","journal-title":"Int Arch Occup Environ Health"},{"key":"2025121605112411000_9.11.e033040.22","doi-asserted-by":"publisher","DOI":"10.1136\/oem.51.4.229"},{"key":"2025121605112411000_9.11.e033040.23","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.6.354"},{"key":"2025121605112411000_9.11.e033040.24","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpba.2019.04.042","article-title":"Validation and uncertainty estimation for trace amounts determination of 25 drugs used in hospital chemotherapy compounding units","volume":"172","author":"Guichard","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"2025121605112411000_9.11.e033040.25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/15563650.2019.1598646","article-title":"Tool development for assessing antineoplastic drugs surface contamination in healthcare services and other workplaces. 39th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 21-24 May 2019, Naples, Italy [abstract]","volume":"57","author":"Atg\u00e9","year":"2019","journal-title":"Clinical Toxicology"},{"key":"2025121605112411000_9.11.e033040.26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/annweh\/wxx070","article-title":"Wipe sampling method and evaluation of environmental variables for assessing surface contamination of 10 antineoplastic drugs by liquid chromatography\/tandem mass spectrometry","volume":"61","author":"Colombo","year":"2017","journal-title":"Ann Work Expo Health"},{"key":"2025121605112411000_9.11.e033040.27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/dta.1827","article-title":"Antineoplastic drugs determination by HPLC-HRMS(n) to monitor occupational exposure","volume":"8","author":"Dal Bello","year":"2016","journal-title":"Drug Test Anal"},{"key":"2025121605112411000_9.11.e033040.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-011-5157-2"},{"key":"2025121605112411000_9.11.e033040.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00100-4"},{"key":"2025121605112411000_9.11.e033040.30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/mas.20046","article-title":"Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs","volume":"24","author":"Stokvis","year":"2005","journal-title":"Mass Spectrom Rev"},{"key":"2025121605112411000_9.11.e033040.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2011.08.034"},{"key":"2025121605112411000_9.11.e033040.32","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.1642"},{"key":"2025121605112411000_9.11.e033040.33","doi-asserted-by":"crossref","unstructured":"Canal-Raffin M , Khennoufa K , Martinez B , et al . Highly sensitive LC-MS\/MS methods for urinary biological monitoring of occupational exposure to cyclophosphamide, ifosfamide, and methotrexate antineoplastic drugs and routine application. J Chromatogr B Analyt Technol Biomed Life Sci 2016 (published Online First: 2016\/12\/29).","DOI":"10.1016\/j.jchromb.2016.10.021"},{"key":"2025121605112411000_9.11.e033040.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-007-0284-y"},{"key":"2025121605112411000_9.11.e033040.35","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1039\/C8AN00479J","article-title":"Biomonitoring of occupational exposure to 5-FU by assaying \u03b1-fluoro-\u03b2-alanine in urine with a highly sensitive UHPLC-MS\/MS method","volume":"143","author":"Dhersin","year":"2018","journal-title":"Analyst"},{"key":"2025121605112411000_9.11.e033040.36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jchromb.2017.06.028","article-title":"A review of high performance liquid chromatographic-mass spectrometric urinary methods for anticancer drug exposure of health care workers","volume":"1060","author":"Mathias","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025121605112411000_9.11.e033040.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-004-0595-1"},{"key":"2025121605112411000_9.11.e033040.38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1078155217726160","article-title":"Survey of guidelines and current practices for safe handling of antineoplastic and other hazardous drugs used in 24 countries","volume":"25","author":"Mathias","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2025121605112411000_9.11.e033040.39","first-page":"87","article-title":"Occupational exposure to antineoplastic drugs in a hospital setting: biological and environmental monitoring]","volume":"29","author":"Barbieri","year":"2005","journal-title":"Epidemiol Prev"},{"key":"2025121605112411000_9.11.e033040.40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/15459624.2016.1237026","article-title":"A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs","volume":"14","author":"Kibby","year":"2017","journal-title":"J Occup Environ Hyg"},{"key":"2025121605112411000_9.11.e033040.41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1177\/1078155218773862","article-title":"Surface contamination with ten antineoplastic drugs in 83 Canadian centers","volume":"25","author":"Chauchat","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2025121605112411000_9.11.e033040.42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.toxlet.2018.05.002","article-title":"Environmental and biological monitoring on an oncology ward during a complete working week","volume":"298","author":"Koller","year":"2018","journal-title":"Toxicol Lett"},{"key":"2025121605112411000_9.11.e033040.43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.2478\/aiht-2018-69-3125","article-title":"A new approach to assessing occupational exposure to antineoplastic drugs in hospital environments","volume":"69","author":"Dugheri","year":"2018","journal-title":"Arh Hig Rada Toksikol"},{"key":"2025121605112411000_9.11.e033040.44","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210369851"},{"key":"2025121605112411000_9.11.e033040.45","first-page":"394","article-title":"Biological monitoring of occupational exposure to antineoplastic drugs in hospital settings","volume":"103","author":"Sabatini","year":"2012","journal-title":"Med Lav"},{"key":"2025121605112411000_9.11.e033040.46","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4212\/cjhp.v69i5.1592","article-title":"Surveillance urinaire des professionnels de la sant\u00e9 expos\u00e9s aux antin\u00e9oplasiques dans le cadre de leur travail : revue de la litt\u00e9rature de 2010 \u00e0 2015","volume":"69","author":"Poupeau","year":"2016","journal-title":"Can J Hosp Pharm"},{"key":"2025121605112411000_9.11.e033040.47","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-015-1026-1"},{"key":"2025121605112411000_9.11.e033040.48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/NCC.0000000000000143","article-title":"Antineoplastic drug exposure in an ambulatory setting","volume":"38","author":"Friese","year":"2015","journal-title":"Cancer Nurs"},{"key":"2025121605112411000_9.11.e033040.49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4212\/cjhp.v68i2.1435","article-title":"Occupational exposure to chemotherapy of pharmacy personnel at a single centre","volume":"68","author":"Ramphal","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"2025121605112411000_9.11.e033040.50","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JOM.0000000000000097","article-title":"Occupational exposure to cyclophosphamide in nurses at a single center","volume":"56","author":"Ramphal","year":"2014","journal-title":"J Occup Environ Med"},{"key":"2025121605112411000_9.11.e033040.51","first-page":"1458","article-title":"Biological monitoring of healthcare workers exposed to antineoplastic drugs: urinary assessment of cyclophosphamide and ifosfamide","volume":"17","author":"Baniasadi","year":"2018","journal-title":"Iran J Pharm Res"},{"key":"2025121605112411000_9.11.e033040.52","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/2165079916662660","article-title":"Occupational exposure to antineoplastic agents","volume":"65","author":"Graeve","year":"2017","journal-title":"Workplace Health Saf"},{"key":"2025121605112411000_9.11.e033040.53","unstructured":"Anonymous . Guideline on bioanalytical method validation. European Medicines Agency, 2011: 23."},{"key":"2025121605112411000_9.11.e033040.54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/15459624.2015.1029618","article-title":"Health Care Workers\u2019 Knowledge, Perceptions, and Behaviors Regarding Antineoplastic Drugs: Survey From British Columbia, Canada","volume":"12","author":"Hon","year":"2015","journal-title":"J Occup Environ Hyg"},{"key":"2025121605112411000_9.11.e033040.55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ajim.22305","article-title":"NIOSH health and safety practices survey of healthcare workers: training and awareness of employer safety procedures","volume":"57","author":"Steege","year":"2014","journal-title":"Am J Ind Med"},{"key":"2025121605112411000_9.11.e033040.56","doi-asserted-by":"publisher","DOI":"10.1188\/12.ONF.E299-E309"},{"key":"2025121605112411000_9.11.e033040.57","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181f72b63"},{"key":"2025121605112411000_9.11.e033040.58","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181f73ae6"},{"key":"2025121605112411000_9.11.e033040.59","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(84)92111-1","article-title":"Occupational exposure to cyclophosphamide","volume":"323","author":"Hirst","year":"1984","journal-title":"The Lancet"},{"key":"2025121605112411000_9.11.e033040.60","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.84.5.852"},{"key":"2025121605112411000_9.11.e033040.61","unstructured":"Anonymous . Biological monitoring of chemical exposure in the workplace guidelines. World Health Organization, 1996: 314."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-033040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:11:39Z","timestamp":1765890699000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-033040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,10]]},"published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1136\/bmjopen-2019-033040"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-033040","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}